Company
Headquarters: Taipei, Taiwan
TW$15.64 Billion
TWD as of July 1, 2024
US$480.5 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, and other forms. It also offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Synmosa Biopharma Corp has the following listings and related stock indices.
Stock: TWSE: 4114 wb_incandescent